Devices Will Fall Under Purview of EU's New Industry Directorate

Friday, November 7, 2014

Source: Clinica

The European Commission's new industry directorate will assume responsibility for medical device policy in the EU, taking over for the health directorate, according to a representative for the commission. Many patient groups and members of the European Parliament oppose the change. The health directorate will still be involved in device policy, however.

View All News »

Devices Will Fall Under Purview of EU's New Industry Directorate

Source: GEN

Bristol-Myers Squibb has purchased an exclusive option to acquire Galecto Biotech depending on the clinical trial performance of Galecto's lead drug candidate TD139, which is in early-stage trials against idiopathic pulmonary fibrosis and other pulmonary fibrotic disorders. The deal could net Galecto as much as $444 million including an option fee, option exercise payment and potential milestone fees.

 

View All News »